Stock Price & Analysis

Based on the provided data and recent market analysis, here's a concise assessment of VTR stock:

Technical Analysis

The stock is showing strong bullish momentum with:

• RSI-14 at 71.84 indicating overbought conditions
• MACD is positive with bullish divergence (MACD: 0.94, Signal: 0.39)
• Trading above all major moving averages (SMA 5,10,20,60,200,250)

Fundamental Strength

Ventas has demonstrated solid performance with:

• Market cap of $25.4 billion
• Outperformed S&P 500 with 31.3% gains over the past year
• Strong senior housing investments totaling $1.4 billion with $300 million more in pipeline

Analyst Consensus

Strong positive sentiment from Wall Street:

• 19 analysts coverage with "Strong Buy" consensus
• 13 "Strong Buy" ratings
• 2 "Moderate Buy" ratings
• 4 "Hold" ratings
• Mean price target of $70.50 (18% upside potential)
• Street-high target of $81 (35.5% upside potential)

Recommendation: SELL

Despite strong fundamentals and positive analyst sentiment, current technical indicators suggest the stock is overbought. The RSI above 70 and recent price surge indicate a potential short-term pullback. Investors should consider taking profits at current levels and wait for a better entry point.

Based on the provided data and recent analyst reports, here's the price prediction for VTR stock in 2025:

VTR stock is expected to reach $67.00 by mid-2025, with a high estimate of $69.00 and a low estimate of $65.00. The prediction is supported by strong fundamentals in healthcare real estate sector and Ventas's diversified portfolio of over 1,300 properties.

The company's recent performance and analyst consensus suggests a bullish trend, with multiple analysts maintaining "Outperform" ratings and positive price targets. The stock's technical indicators show strong momentum with RSI at 71.84 and positive MACD divergence, supporting the upward price trajectory.

The S1 support level for VTR Stock is $59.98 ,The R1 resistant level for VTR Stock is $66.71.

As of the end of day on 2025-02-21, the price of VTR Stock was $66.08.

The target price for VTR Stock according to analyst rating is 69.70, with the highest price target at 76.00 and the lowest at 65.00. Analysts have a Strong Buy rating on VTR Stock overall.

The market cap of VTR is $28.9B.

Based on the provided data and recent analyst coverage, here's a comprehensive analysis of VTR's valuation:

Technical Analysis

The stock is currently showing signs of being overvalued based on technical indicators:

• RSI-14 at 71.84 indicates overbought conditions
• Trading above all major moving averages (5,10,20,60,200,250-day)
• Bollinger Band Position (BBP) at 1.02 suggests price is near the upper band

Fundamental Valuation

Metric	2023 Value
EV/EBITDA	38.94x
P/S	4.45x
P/B	2.05x
Dividend Yield	4.22%

The current valuation metrics suggest VTR is trading at premium multiples:

• EV/EBITDA of 38.94x is significantly higher than historical averages
• P/S ratio of 4.45x indicates premium pricing relative to revenue
• P/B ratio of 2.05x suggests the stock trades above book value

Analyst Consensus

According to recent analyst coverage:

• Strong Buy consensus from 19 analysts
• Mean price target of $70.50 (18% upside)
• 13 Strong Buys, 2 Moderate Buys, 4 Holds
• Recent price target raise to $69 by Scotiabank

Financial Performance

The company faces some challenges:

• Revenue growth of 8.9% YoY to $4.49B in 2023
• Negative net margin of -0.67% in 2023
• High debt-to-equity ratio of 137%
• Low current ratio of 0.23x

Conclusion

VTR appears overvalued at current levels based on:

1. Overbought technical indicators
2. Premium valuation multiples
3. Weak profitability metrics
4. High leverage ratios

While analysts remain bullish on the stock's long-term prospects due to strategic healthcare investments and aging population trends, the current valuation suggests limited upside potential in the near term.

Ventas, Inc. is a real estate investment trust (REIT). The Company’s portfolio includes senior housing communities, which provide valuable services to residents. The Company leverages its operational expertise and data-driven insights from its Ventas Operational Insights platform. The Company’s portfolio consists of approximately 1,400 properties. The Company’s portfolio also includes outpatient medical buildings, research centers and healthcare facilities in North America and the United Kingdom. The Company, through its Senior Housing Operating Portfolio segment, invests in senior housing communities. Through its Outpatient Medical and Research Portfolio segment, it primarily acquires, owns, develops, leases, and manages outpatient medical buildings and research centers. Through its Triple-Net Leased Properties segment, it invests in and owns senior housing communities, skilled nursing facilities (SNFs), long-term acute care facilities (LTACs), and other healthcare facilities.

Based on the available data and analyst insights, here's a projection for VTR stock price in 2030:

Ventas (VTR) stock is projected to reach $85-90 by 2030, representing a potential upside of approximately 28-35% from current levels. This forecast is supported by three key factors:

1. Strong healthcare real estate portfolio fundamentals and demographic tailwinds. The company's diversified healthcare portfolio of over 1,300 properties positions it well to benefit from aging population trends.

2. Robust financial metrics with improving revenue growth of 7.52% and healthy debt management with a debt-to-equity ratio of 1.42, suggesting sustainable long-term growth potential.

3. Recent analyst consensus shows bullish sentiment with price targets ranging from $65-69 in the near term, indicating strong growth momentum that could continue through 2030.

VTR has a total of 486 employees.